Ligand Pharmaceuticals Incorporated

Total Valuation

Ligand Pharmaceuticals Incorporated carries a market capitalization of 5.16B, placing it among publicly traded companies globally. Its enterprise value stands at 3.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Ligand Pharmaceuticals Incorporated currently has 20.03M shares outstanding.

Valuation Ratios

Ligand Pharmaceuticals Incorporated trades at a trailing price-to-earnings ratio of 25.52. The price-to-sales ratio is 14.28, and the price-to-book ratio stands at 6.59.

Enterprise Valuation

On an enterprise value basis, Ligand Pharmaceuticals Incorporated trades at an EV/EBITDA multiple of 26.62 and an EV/FCF ratio of 26.00. The EV/Sales ratio of 13.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 35.36 provides insight into valuation relative to core operating earnings.

Financial Position

Ligand Pharmaceuticals Incorporated maintains a current ratio of 21.28, meaning it holds 21.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.32, indicating elevated leverage, while an interest coverage ratio of 24.03 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Ligand Pharmaceuticals Incorporated posts a return on equity of 29.21 and a return on invested capital of 7.44.

Taxes

Over the trailing twelve months, Ligand Pharmaceuticals Incorporated has paid 31.32M in income taxes, reflecting an effective tax rate of 16.94.

Stock Price Statistics

Ligand Pharmaceuticals Incorporated's stock has gained approximately 122.9266% over the past 52 weeks. The 50-day moving average sits at 223.92, while the 200-day moving average is 198.43.

Income Statement

Over the trailing twelve months, Ligand Pharmaceuticals Incorporated generated 274.48M in revenue and converted that into 153.56M in net income, yielding earnings per share of 7.53. EBITDA reached 134.45M, while operating income came in at 101.23M.

Balance Sheet

Ligand Pharmaceuticals Incorporated holds 791.56M in cash and equivalents against 451.98M in total debt, resulting in a net debt position of 331.82M. Total book value stands at 594.76M, with working capital of 824.75M providing operational flexibility.

Cash Flow

Ligand Pharmaceuticals Incorporated produced 123.50M in operating cash flow over the past twelve months. After subtracting -9.51M in capital expenditures, free cash flow totaled 113.99M - equivalent to 5.81 per share.

Margins

Ligand Pharmaceuticals Incorporated operates with a gross margin of 95.27, reflecting its pricing power and cost economics. The operating margin of 36.88 and net profit margin of 55.95 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Ligand Pharmaceuticals Incorporated's most recent stock split took place on November 2, 2022 with a 1000:1603 split ratio.

Scores

Ligand Pharmaceuticals Incorporated posts an Altman Z-Score of 6.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.